GB9916882D0
(en)
*
|
1999-07-19 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Antitumor synergistic composition
|
EP1496897A4
(en)
|
2002-04-12 |
2006-05-10 |
Merck & Co Inc |
INHIBITORS OF TYROSINE KINASES
|
EP1542989B1
(en)
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
ATE380810T1
(de)
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
DE10354060A1
(de)
|
2003-11-19 |
2005-06-02 |
Merck Patent Gmbh |
Pyrrolderivate
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
CN100438913C
(zh)
*
|
2004-11-22 |
2008-12-03 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100402091C
(zh)
*
|
2005-02-03 |
2008-07-16 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100350974C
(zh)
*
|
2005-02-03 |
2007-11-28 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
DE102005016634A1
(de)
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
CA2605738C
(en)
|
2005-04-25 |
2013-10-01 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Novel azaheterocyclic compounds as kinase inhibitors
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
DE102005061840A1
(de)
|
2005-12-23 |
2007-06-28 |
Merck Patent Gmbh |
Triazolderivate
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP2010514777A
(ja)
|
2006-12-26 |
2010-05-06 |
ファーマサイクリックス,インク. |
併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
|
DE102007008419A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
DE102007013856A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydropyrrolochinoline
|
DE102007013854A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
DE102007013855A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydrochinoline
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
DE102007028515A1
(de)
|
2007-06-21 |
2008-12-24 |
Merck Patent Gmbh |
6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
DE102007047737A1
(de)
|
2007-10-05 |
2009-04-30 |
Merck Patent Gmbh |
Piperidin- und Piperazinderivate
|
DE102007047735A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Thiazolderivate
|
DE102007047738A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Imidazolderivate
|
DE102007049451A1
(de)
|
2007-10-16 |
2009-04-23 |
Merck Patent Gmbh |
5-Cyano-thienopyridine
|
US9486497B2
(en)
|
2007-12-10 |
2016-11-08 |
The University Of Queensland |
Treatment of immunocompromised conditions
|
US8466151B2
(en)
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
DE102008005493A1
(de)
|
2008-01-22 |
2009-07-23 |
Merck Patent Gmbh |
4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
|
DE102008017853A1
(de)
|
2008-04-09 |
2009-10-15 |
Merck Patent Gmbh |
Thienopyrimidine
|
JP5670877B2
(ja)
|
2008-04-15 |
2015-02-18 |
ファーマサイクリックス,インク. |
ヒストン脱アセチル化酵素の選択的インヒビター
|
DE102008025751A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
|
DE102008027574A1
(de)
|
2008-06-10 |
2009-12-17 |
Merck Patent Gmbh |
Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
|
DE102008031517A1
(de)
|
2008-07-03 |
2010-01-07 |
Merck Patent Gmbh |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
DE102008059578A1
(de)
|
2008-11-28 |
2010-06-10 |
Merck Patent Gmbh |
Benzo-Naphtyridin Verbindungen
|
DE102009005193A1
(de)
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
JP5779172B2
(ja)
|
2009-04-02 |
2015-09-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
オートタキシン阻害剤
|
EP2623101B1
(en)
|
2009-04-02 |
2021-04-21 |
Merck Patent GmbH |
Piperidine and piperazine derivatives as autotaxin inhibitors
|
KR20120027192A
(ko)
|
2009-04-02 |
2012-03-21 |
메르크 파텐트 게엠베하 |
오토탁신 저해제로서의 헤테로시클릭 화합물
|
DE102009019962A1
(de)
|
2009-05-05 |
2010-11-11 |
Merck Patent Gmbh |
3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
DE102009033208A1
(de)
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
DE102009033392A1
(de)
|
2009-07-16 |
2011-01-20 |
Merck Patent Gmbh |
Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
|
ES2745255T3
(es)
|
2009-08-26 |
2020-02-28 |
Alberta Health Services |
Derivados de colchicina novedosos, métodos y usos de los mismos
|
DE102009049211A1
(de)
|
2009-10-13 |
2011-04-28 |
Merck Patent Gmbh |
Sulfoxide
|
CN102638981B
(zh)
|
2009-10-14 |
2015-07-22 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
MX2012005250A
(es)
|
2009-11-07 |
2012-06-14 |
Merck Patent Gmbh |
Heteroarilaminoquinolinas como inhibidores de cinasa del receptor tgf-beta.
|
DE102009060174A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
DE102009060175A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
WO2011115725A2
(en)
|
2010-03-16 |
2011-09-22 |
Dana-Farber Cancer Institute, Inc. |
Indazole compounds and their uses
|
CN102822171B
(zh)
|
2010-03-26 |
2015-09-02 |
默克专利有限公司 |
作为自分泌运动因子抑制剂的苯并萘啶胺类
|
WO2011120153A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
ES2792799T3
(es)
|
2010-06-28 |
2020-11-12 |
Merck Patent Gmbh |
[1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
|
US8846931B2
(en)
|
2010-07-05 |
2014-09-30 |
Merck Patent Gmbh |
Bipyridyl derivatives
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2611808B1
(en)
|
2010-09-02 |
2014-11-12 |
Merck Patent GmbH |
Pyrazolopyridinone derivatives as lpa receptor antagonists
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
DE102010048374A1
(de)
|
2010-10-13 |
2012-04-19 |
Merck Patent Gmbh |
Pyrrolidinone als MetAP-2 Inhibitoren
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
DE102010050558A1
(de)
|
2010-11-05 |
2012-05-10 |
Merck Patent Gmbh |
1H-Pyrrolo[2,3-b]pyridinderivate
|
DE102010053347A1
(de)
|
2010-12-03 |
2012-06-06 |
Merck Patent Gmbh |
3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
DE102011008352A1
(de)
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
DE102011009961A1
(de)
|
2011-02-01 |
2012-08-02 |
Merck Patent Gmbh |
7-Azaindolderivate
|
KR20140022829A
(ko)
|
2011-03-09 |
2014-02-25 |
메르크 파텐트 게엠베하 |
피리도 [2, 3 - b] 피라진 유도체 및 그 치료적 용도
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2714677B1
(en)
|
2011-05-23 |
2018-08-22 |
Merck Patent GmbH |
Pyridine-and pyrazine derivatives
|
CN103717609B
(zh)
|
2011-05-31 |
2016-05-11 |
江苏康缘药业股份有限公司 |
聚(adp-核糖)聚合酶的三环抑制剂
|
DE102011105469A1
(de)
|
2011-06-24 |
2012-12-27 |
Merck Patent Gmbh |
7-Azaindolderivate
|
AU2012294917A1
(en)
|
2011-08-10 |
2014-03-20 |
Merck Patent Gmbh |
Pyrido-pyrimidine derivatives
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
RU2622034C2
(ru)
|
2012-02-09 |
2017-06-09 |
Мерк Патент Гмбх |
ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
|
DE102012006884A1
(de)
|
2012-04-04 |
2013-10-10 |
Merck Patent Gmbh |
Cyclische Amide als MetAP-2 Inhibitoren
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
DE102012019369A1
(de)
|
2012-10-02 |
2014-04-03 |
Merck Patent Gmbh |
7-Azaindolderivat
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
US9655899B2
(en)
|
2012-11-28 |
2017-05-23 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
TW201429969A
(zh)
|
2012-12-20 |
2014-08-01 |
Merck Sharp & Dohme |
作爲hdm2抑制劑之經取代咪唑吡啶
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JP6464395B2
(ja)
|
2013-06-06 |
2019-02-06 |
リード ディスカヴァリー センター ゲーエムベーハーLead Discovery Center GmbH |
マクロファージを刺激する1受容体mstr1のキノリン阻害剤
|
WO2015034928A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN105849099B
(zh)
|
2013-10-18 |
2020-01-17 |
达纳-法伯癌症研究所股份有限公司 |
周期蛋白依赖性激酶7(cdk7)的多环抑制剂
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
CA2968391C
(en)
|
2014-12-03 |
2022-04-26 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US10933049B2
(en)
|
2015-06-03 |
2021-03-02 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017151708A1
(en)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
|
WO2017222951A1
(en)
|
2016-06-23 |
2017-12-28 |
Merck Sharp & Dohme Corp. |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
EP3497131B1
(en)
|
2016-08-08 |
2022-03-09 |
GlycoMimetics, Inc. |
Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
CN117298287A
(zh)
|
2016-10-07 |
2023-12-29 |
糖模拟物有限公司 |
高效的多聚体e-选择蛋白拮抗剂
|
JP7272956B2
(ja)
|
2017-03-15 |
2023-05-12 |
グリコミメティクス, インコーポレイテッド |
E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体
|
JP7160833B2
(ja)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
抗sirpアルファ抗体
|
DK3668516T3
(da)
|
2017-08-16 |
2021-12-13 |
Merck Patent Gmbh |
Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2019108750A1
(en)
|
2017-11-30 |
2019-06-06 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
EP3732186A1
(en)
|
2017-12-29 |
2020-11-04 |
GlycoMimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CA3091454A1
(en)
|
2018-03-05 |
2019-09-12 |
Glycomimetics, Inc. |
Methods for treating acute myeloid leukemia and related conditions
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020139962A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
MX2022007535A
(es)
|
2019-12-17 |
2022-09-23 |
Merck Sharp & Dohme Llc |
Inhibidores de prmt5.
|